Core Points - The 21st "Dabeinong Cup" Healthy Pig Farming Technology Competition has officially launched, focusing on feed nutrition [6][15] - The competition will assess feed quality using simulated digestion methods, with evaluation criteria including feed quality and comprehensive assessment of pig source organization and African swine fever nucleic acid testing [9][10] - Awards will be presented for each of the eight feed categories during the 52nd Pig Industry Conference in Guangzhou from December 11-13, 2025 [14] Competition Details - The competition is organized by the Guangdong Agricultural Technology Promotion Center, with support from Southern Rural News, Agricultural Finance and Economics, and New Livestock Network, and is exclusively sponsored by Dabeinong Feed [15][16] - Participating pig farms can include family farms, large-scale farms, and fattening farms that comply with laws and regulations and are committed to healthy farming practices [18][19] - Each participating farm must submit samples of 1-8 types of feed, with a minimum of 50 grams per sample, and is encouraged to submit all eight types for a comprehensive evaluation [28][30] Evaluation Process - Samples will be sent to the Agricultural Rural Ministry's Pig Quality Supervision and Inspection Testing Center in Guangzhou for comprehensive scoring based on testing results [36][38] - The competition will maintain confidentiality regarding the data of all participating farms, only publishing the names of the winning farms without disclosing specific feed brands used [40][41] - The top three farms in each feed category will be awarded first, second, and third prizes, with one winner per category [42]

Core Viewpoint - TianKang Biological has reported a significant turnaround in its financial performance for 2024, achieving a net profit of 605 million yuan, compared to a loss in the previous year, indicating a successful V-shaped recovery in its operations [1][2]. Group 1: Financial Performance - The company achieved total operating revenue of 17.176 billion yuan, with a notable increase in profit margins across its three main business segments: pig farming, feed, and veterinary medicine [1]. - The pig farming segment generated revenue of 6.157 billion yuan, reflecting an 11.11% increase year-on-year, with a gross margin of 14.61%, up by 28.43% from the previous year [2]. Group 2: Business Structure and Capabilities - TianKang Biological is recognized as a key agricultural enterprise in China, with a complete industry chain covering breeding, feed management, veterinary medicine, and meat processing [1]. - The company operates over 30 feed production facilities nationwide and ranks among the top 20 in the national feed industry [1]. Group 3: Research and Development - The company has invested over 15% of its biopharmaceutical sales revenue into R&D, establishing research centers in Xinjiang and Jiangsu [2]. - It has developed China's first genetically engineered inactivated vaccine for swine fever, providing significant support for disease control in pigs [2]. Group 4: Future Outlook - TianKang Biological aims to achieve a total revenue of 21 billion yuan by 2025, with specific targets for feed production, animal vaccines, and pig output [3]. - The company plans to enhance its service offerings to farmers, focusing on key areas such as feed, breeding, and veterinary services to improve farming efficiency [3]. Group 5: Shareholder Returns - The company has proposed a cash dividend of 2.20 yuan per 10 shares, translating to an approximate dividend yield of 3.52% based on the closing price on April 28 [3].